The RAPIDO randomized trial examined whether a short-course radiotherapy strategy followed by systemic chemotherapy before total mesorectal excision could reduce treatment failure in patients with high-risk locally advanced rectal cancer. The study compared this experimental total-neoadjuvant approach with standard chemoradiotherapy followed by surgery and optional postoperative chemotherapy. At three years, the experimental strategy produced a lower rate of treatment failure than standard management. The result was important because it showed that moving systemic therapy earlier in the treatment pathway can improve disease control in a population at substantial risk of distant and local failure. RAPIDO also helped accelerate wider interest in total neoadjuvant therapy for rectal cancer. The clinically useful lesson is not that one regimen should replace every other approach. Rather, treatment sequencing can be deliberately designed around the patient's risk profile, treatment tolerance and the need to deliver systemic therapy reliably before surgery. The trial reinforced the role of multidisciplinary planning, high-quality MRI staging and careful selection of patients with adverse disease features. RAPIDO is therefore particularly relevant to contemporary rectal cancer practice, where decisions increasingly focus on optimizing the entire neoadjuvant pathway rather than viewing surgery as the sole definitive intervention.